Clinical Trials Browser

Active not recruiting × lenvatinib × Head & Neck × Clear all

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Phase 2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms